FLUTAMIDE


Trade Names	EULEXIN FLUTAMIDE
Synonyms	Chimax Drogenil Eulexin Flutamide NSC-215876 SCH 13521 SCH-13521
Status
Molecule Category	UNKNOWN
ATC	L02BB01
UNII	76W6J0943E
EPA CompTox	DTXSID7032004


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MKXKFYHWDHIYRV-UHFFFAOYSA-N
Smiles	CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
InChI	InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C11H11F3N2O3
Molecular Weight	276.21
AlogP	3.21
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	72.24
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	19.0

Pharmacology

Mechanism of Action	Action	Reference
Androgen Receptor antagonist	ANTAGONIST	FDA


Protein: Androgen Receptor Description: Androgen receptor Organism : Homo sapiens P10275 ENSG00000169083

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	600-14000	-
Enzyme Oxidoreductase	-	-	-	-	11-19
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4	-	154-4200	-	1300-3700	12-20
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	7-131
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	34
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	50000-75000	-	-	-

Cross References

Resources	Reference
ChEBI	5132
ChEMBL	CHEMBL806
DrugBank	DB00499
DrugCentral	1223
FDA SRS	76W6J0943E
Human Metabolome Database	HMDB0014642
Guide to Pharmacology	6943
KEGG	C07653
PharmGKB	PA449685
PubChem	3397
SureChEMBL	SCHEMBL3934
ZINC	ZINC000003812944

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).